Trials / Not Yet Recruiting
Not Yet RecruitingNCT07133490
INTERACT Stomach-II
Intraperitoneal Irinotecan Combined With Systemic Therapy for Patients With Gastric Peritoneal Metastases: A Phase II, Multicenter Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- Sponsor
- Erasmus Medical Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a phase II study conducted in three hospitals in the Netherlands (Erasmus MC in Rotterdam, Catharina Hospital in Eindhoven, and the Netherlands Cancer Institute in Amsterdam). A total of 49 patients will take part. The aim is to test whether a new combination treatment is feasible for patients with gastric peritoneal metastases (PM). The treatment includes chemotherapy (intraperitoneal irinotecan and standard systemic therapy such as CAPOX or FOLFOX), and may also include nivolumab or trastuzumab, depending on biomarker results.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intraperitoneal chemotherapy | Through a peritoneal access port, irinotecan will be administered at the same time as systemic (chemo)therapy |
Timeline
- Start date
- 2025-10-01
- Primary completion
- 2027-10-01
- Completion
- 2028-07-01
- First posted
- 2025-08-21
- Last updated
- 2025-08-21
Source: ClinicalTrials.gov record NCT07133490. Inclusion in this directory is not an endorsement.